H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECHâ„¢ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...
The first two and some forms of obesity are associated with single-point mutations. Some other companies using ADAR enzymes ...
Also Read: Gene Editing Korro Bio’s Preclinical Data ‘Best-In-Class’, Analyst Initiates With Outperform Rating In a company presentation, preliminary safety data (N=6) showed an initial ...
Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).
Who is Atlas Venture Opportunity Fund II, L.P.? Atlas Venture Opportunity Fund II, L.P. has an estimated net worth of $27.1 Million. This is based on reported shares across multiple companies ...
Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback